Background illustration for clinical trials search

Paid Clinical Trials Glendale

Discover 3,600 paid clinical trials in Glendale, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

for
Metastatic Colorectal Adenocarcinoma,
Location: Los Angeles CA, Orange CA, Costa Mesa CA, Irvine CA,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06102902

Phase 1, Recruiting

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

for
Solid Tumours
Location: Los Angeles CA, Orange CA, West Valley City UT,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT07160725

Phase 1, Phase 2, Recruiting

Qualitative Study on Detection & Tx of NSCLC in Pts w/ a History of Alcohol or SUD

for
Lung Non-Small Cell Carcinoma, Thoracic Cancer
Location: Los Angeles CA
Sponsor: University of Southern California

Sex: All

Age: 18+

Code: NCT07186699

Recruiting

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

for
Non-Small-Cell Lung Cancer,
Location: Los Angeles CA, Fullerton CA, Orange CA,
Sponsor: ArriVent BioPharma, Inc.

Sex: All

Age: 18+

Code: NCT07185997

Phase 3, Recruiting

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

for
Advanced Or Metastatic Merkel Cell Carcinoma
Location: Los Angeles CA, Stanford CA, San Francisco CA,
Sponsor: TuHURA Biosciences, Inc.

Sex: All

Age: 18+

Code: NCT06947928

Phase 2, Phase 3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

for
Bladder Cancer, Squamous Cell Carcinoma of the Lung,
Location: Los Angeles CA, Duarte CA, San Francisco CA, Houston TX,
Sponsor: EvolveImmune United, Inc

Sex: All

Age: 18+

Code: NCT07217171

Phase 1, Recruiting

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

for
Extensive Stage Small Cell Lung Cancer
Location: Los Angeles CA, Seattle WA, Sioux Falls SD, St Louis MO,
Sponsor: Amgen

Sex: All

Age: 18 - 70+

Code: NCT07037758

Phase 1, Recruiting

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

for
Breast Neoplasms
Location: Los Angeles CA, Portland OR, Loveland CO, Greeley CO,
Sponsor: Eli Lilly and Company

Sex: Female

Age: 18+

Code: NCT07287098

Phase 2, Recruiting

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

for
Endometrial Cancer
Location: Los Angeles CA, Reno NV, Murray UT, Aurora CO,
Sponsor: BioNTech SE

Sex: Female

Age: 18+

Code: NCT06340568

Phase 3, Recruiting

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

for
Cervical Squamous Cell Carcinoma,
Location: Los Angeles CA, Phoenix AZ, San Antonio TX, Houston TX,
Sponsor: Alentis Therapeutics AG

Sex: All

Age: 18+

Code: NCT07169734

Phase 1, Phase 2, Recruiting

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

for
Immune Thrombocytopenia (ITP)
Location: Los Angeles CA, Palo Alto CA, Austin TX,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT06721013

Phase 1, Phase 2, Recruiting

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

for
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Location: Los Angeles CA, Phoenix AZ, Tucson AZ,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT07063745

Phase 2, Phase 3, Recruiting

A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Indian and Alaska Native Cancer Patients Living in Rural California

for
Hematopoietic and Lymphatic System Neoplasm,
Location: Los Angeles CA, Bishop CA
Sponsor: University of Southern California

Sex: All

Age: 0+

Code: NCT07332312

Recruiting

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

for
Head and Neck Squamous Cell Carcinoma (HNSCC),
Location: Los Angeles CA, West Valley City UT, San Antonio TX,
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT05985655

Phase 1, Phase 2, Recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

for
Breast Neoplasms
Location: Los Angeles CA, Cerritos CA, Newport Beach CA,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT06926868

Phase 2, Phase 3, Recruiting

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

for
Esophageal Squamous Cell Carcinoma
Location: Los Angeles CA, Fullerton CA, Orange CA, Phoenix AZ,
Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT06644781

Phase 3, Recruiting

Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer

for
Breast Carcinoma
Location: Los Angeles CA
Sponsor: University of Southern California

Sex: Female

Age: 30 - 70+

Code: NCT07076147

Recruiting

Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers

for
Healthy Subject, Hematologic and Lymphocytic Disorder,
Location: Los Angeles CA
Sponsor: University of Southern California

Sex: All

Age: 19+

Code: NCT03207854

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

for
Colorectal Cancer
Location: Los Angeles CA, Fullerton CA, Portland OR,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07023289

Phase 2, Recruiting

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

for
Non-Squamous Non-Small Cell Lung Cancer, c-MET
Location: Los Angeles CA, Santa Monica CA, Duarte CA, Upland CA,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07005102

Phase 2, Phase 3, Recruiting